Stay updated on FG-3019 in Hepatitis B Liver Fibrosis Clinical Trial

Sign up to get notified when there's something new on the FG-3019 in Hepatitis B Liver Fibrosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the FG-3019 in Hepatitis B Liver Fibrosis Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the efficacy evaluation of FG-3019 for reversing liver fibrosis in subjects with chronic hepatitis B infection who are starting antiviral therapy with entecavir.
    Difference
    0.2%
    Check dated 2024-06-06T14:25:18.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying requirements such as signed informed consent, age range, HBsAg positivity duration, and liver fibrosis confirmation. Previously, this section indicated that no information was provided.
    Difference
    20%
    Check dated 2024-05-22T21:13:06.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:54:50.000Z thumbnail image

Stay in the know with updates to FG-3019 in Hepatitis B Liver Fibrosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the FG-3019 in Hepatitis B Liver Fibrosis Clinical Trial page.